Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.

Mir Lim Maishara Muquith Bernadette Miramontes Magdalena Espinoza David Hsiehchen

Published in: Cancer research communications (2023)

Treatment beyond progression with ICIs in patients with HCC is safe and may benefit a subset of patients due to later-onset tumor responses or disease stability. These findings may guide the design of trials testing ICIs in HCC and the use of treatment beyond progression in routine practice.

Keyphrases

healthcare
primary care
newly diagnosed
prognostic factors
patient reported outcomes
quality improvement
patient reported